Thermo Fisher Scientific Ranibizumab Monoclonal Antibody (10D12)

Applications

Tested Dilution

Publications

ELISA (ELISA)

0.01-0.1 µg/mL

-

Product Specifications

Species Reactivity

Human

Host/Isotype

Mouse / IgG1, kappa

Class

Monoclonal

Type

Antibody

Clone

10D12

Immunogen

Ranibizumab

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Lyophilized

Purification

Protein A

Storage buffer

PBS, pH 7.4

Contains

0.02% sodium azide

Storage conditions

-20°C or -80°C if preferred

Shipping conditions

Ambient (domestic); Wet ice (international)

Product Specific Information

Reconstitute the lyophilized antibody with deionized water (or equivalent) to a final concentration of 0.5 mg/ml.

Ranibizumab with trade name Lucentis, is an FDA-approved drug for the treatment of patients with neovascular (Wet) age-related macular degeneration (AMD) and macular edema following retinal vein occlusion (RVO). It is a recombinant humanized IgG1 kappa isotype monoclonal antibody fragment. Ranibizumab binds to vascular endothelial growth factor A (VEGF-A) and blocks its activity.Anti-Ranibizumab Antibody (10D12), mAb, Mouse is produced from a hybridoma resulting from the fusion of partner and B-lymphocytes obtained from a mouse immunized with Ranibizumab.

Target Information

Ranibizumab with trade name Lucentis, is an FDA-approved drug for the treatment of patients with neovascular (Wet) age-related macular degeneration (AMD) and macular edema following retinal vein occlusion (RVO). It is a recombinant humanized IgG1 kappa isotype monoclonal antibody fragment. Ranibizumab binds to vascular endothelial growth factor A (VEGF-A) and blocks its activity.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.